KYMRKymera Therapeutics, Inc.

1. Aug 5, 2026Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update.Earnings release · press release
2. Jul 27, 2026Jared Gollob, M.D., communicated his intention to retire from his role as Chief Medical Officer (“CMO”) of Kymera Therapeutics, Inc. (the “Company”) and submitted his resignation on July 27, 2026.Director or officer change · Form 8-K
3. Jun 25, 2026On June 25, 2026, the Company announced that it has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, its first-in-class, oral STAT6 degrader, for the treatment of moderate to severe atopic dermatitis (“AD”)Regulation FD disclosure · Form 8-K
4. Jun 8, 2026Jeremy Chadwick communicated his intention to retire and submitted his resignation as Chief Operating Officer (“COO”) on June 5, 2026. Mr. Chadwick will remain an employee of Kymera Therapeutics, Inc. (the “Company”) as an advisor until November 2026.Director or officer change · Form 8-K
5. Apr 30, 2026Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update.Earnings release · press release
6. Mar 27, 2026The Board approved the Bylaw Amendment in response to recent amendments to the General Corporation Law of the State of Delaware regarding such forum selection provisions.Charter/bylaw amendment or fiscal-year change · Form 8-K
7. Feb 26, 2026On February 26, 2026, Kymera Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “TD Cowen Sales Agreement”), with TD Securities (USA) LLC (“TD Cowen”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at the Company’s sole discretion …Material agreement entered · Form 8-K
8. Feb 26, 2026Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update.Earnings release · press release
9. Jan 13, 2026Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance.Earnings release · press release
10. Dec 10, 2025Follow-on Offering On December 9, 2025, Kymera Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC and Wells Fargo …Material agreement entered · Form 8-K
11. Dec 8, 2025Agenda Introduction Justine Koenigsberg Vice President, Investor.Regulation FD disclosure · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.